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Abstract
Introduction: Alzheimer’s disease is a debilitating condition, and the search for an effective treatment is ongoing.
Inflammation, in reaction to amyloid deposition, is thought to accelerate cognitive decline. With tumor necrosis
factor α being an important proinflammatory cytokine, a recent trial investigated the effect of the tumor necrosis
factor α inhibitor etanercept after peripheral administration in patients with Alzheimer’s disease. Although there was
no significant effect, others have claimed spectacular effects of etanercept after perispinal injection. In the present
study, the central delivery of drugs with a large molecular weight was evaluated after injection in the cervical perispinal
region in rats. If successful, this strategy might increase therapeutic options for patients with Alzheimer’s disease.
Methods: Nine male Sprague–Dawley rats were given injections of iodine-125–labeled cetuximab (146 kDa),
etanercept (51 kDa), and anakinra (17 kDa). Each radioiodinated drug was injected in the perispinal region in
two rats and into the dorsal tail vein in one rat. Directly after injection, the rats were placed in a head-down
position for 3 minutes to direct blood flow into the valveless vertebral venous system. A single-positron emission
computed tomography scan was acquired starting 5 minutes after injection, subsequently the rats were euthanized and
bio-distribution was determined.
Results: Intracranial delivery of the radiolabeled drugs could not be visualized in all but one of the rats. Injected drugs
accumulated locally in the perispinal region.
Conclusions: In this study, no evidence could be found for the delivery of drugs to the central nervous system after
perispinal injection. Additional research is needed before this treatment can be used in patients with Alzheimer’s disease.
Introduction
During the past few years, there has been an increase in
the use of targeted therapies for different kinds of in-
flammatory disorders. Most of these drugs, including
the tumor necrosis factor α (TNF-α) inhibitor etaner-
cept, have a high molecular weight, which prohibits
them from passing the blood–brain barrier (BBB). This
is no problem when treating diseases such as rheuma-
toid arthritis, but it becomes an obstacle when the
brain is the primary focus of inflammation. The latter
is presumed to be the case in brain injury in Alzhei-
mer’s disease (AD). It is suspected that inflammation,
as a consequence of amyloid deposition, plays an im-
portant role in the cognitive decline in AD [1, 2] and
that the intensity of this inflammatory reaction influ-
ences the speed of cognitive decline in individual
patients [3].
TNF-α is a proinflammatory cytokine known for its
activity in several disease conditions [4]. It plays an im-
portant role in immune-to-brain communication [5],
and increased TNF-α is associated with rapid neurocog-
nitive decline [6] and neuropsychiatric symptoms [7] in
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AD. The effect of peripheral inhibition of TNF-α in AD
was assessed recently in a trial evaluating the effect of
etanercept and placebo in 41 patients with AD [8]. Al-
though the drug was well tolerated, there were no signifi-
cant effects on cognitive function and behavior. However,
earlier uncontrolled studies by Tobininick et al, claim
benefit from perispinal administration of etanercept in
AD [9, 10] and post-stroke patients [11]. If true, these re-
sults, which were heavily criticized by Whitlock [12],
would open up potential new treatment avenues.
The first question to be asked is whether there is a
causal relationship between increased TNF-α activity
and cognitive decline in AD. As mentioned above, the
role of inflammation in AD has not been fully eluci-
dated. Therefore, TNF-α inhibition as a strategy in this
category of patients is questionable. A recent phase II
study using peripheral etanercept administration in pa-
tients with AD was ineffective [8]. Still, this lack of an ef-
fect could have been caused by insufficient inhibition of
TNF-α in the central nervous system (CNS) after periph-
eral administration. This leads to the second question,
which is; Does perispinal administration of drugs with a
high molecular weight lead to adequate concentrations in
the brain? Etanercept does not cross the BBB after periph-
eral administration, because of its high molecular weight
(51 kDa). Tobinick searched for a method to bypass the
BBB without having to use more harmful methods of ad-
ministering drugs and relied on the vertebral venous sys-
tem (VVS) to accomplish this [9].
In humans, the musculature and the (sub)cutaneous
tissues of the back and neck are drained by the external
vertebral venous plexus (EVVP) [13, 14]. The EVVP con-
nects with the internal vertebral venous plexus, and both
plexuses connect with the basivertebral veins. These
three venous entities represent the VVS, also known as
the Batson venous plexus, which is thought to be valve-
less and forms a separate and discrete venous network
paralleling, joining, and at the same time bypassing, the
longitudinal veins of the thoracoabdominal cavity. The
VVS also connects with the intracranial basilar venous
plexus and the intracranial dural sinuses [15]. In nonhu-
man primates, Batson injected radiopaque material into
the deep dorsal vein of the penis and demonstrated the
existence of a connection between the pelvic venous
plexus with the VVS. He also showed that the contrast
medium can be redirected into the intracranial venous
sinuses after compression (and subsequent temporary
obstruction of the inferior vena cava) of the abdomen
[13]. In his study, he found an explanation for the obser-
vation that metastases of retroperitoneal cancers in
humans tend to preferentially distribute to the vertebral
skeleton and spinal epidural space and via the cranial si-
nuses into the brain. Based on these findings and as-
sumptions, Tobinick designed his concept for drug
delivery into the brain [9]. He assumed that, after injec-
tion into the perispinal soft tissues and subsequently
placing the patient in the Trendelenburg position, the
retrograde flow within the VVS would result in the de-
livery of the medication through the cranial veins into
the brain. Tobinick et al. have performed and published
only one single experiment in rats, visualizing the intra-
cranial distribution of etanercept labeled with the positron
emitter Cu-64 [16], and speculate about the mechanism
without providing further proof [17]. Positron emission
tomography studies in healthy controls or patients have
not been performed to date.
In this brief article, the methods published by Tobinick
were explored by injecting drugs with a large molecular
weight into the cervical perispinal region of Sprague–
Dawley rats. As this technique is claimed to be a safe
and effective way to administer drugs to the CNS, it could
provide a new treatment option for patients with AD.
Methods
Ethical approval
Ethical approval was obtained to conduct the described
animal experiments. All study procedures involving ani-
mals were performed in accordance with the Dutch Exper-
iments on Animals Act and the ethical standards of the
institution at which the study was conducted (Radboud
University Medical Center, Nijmegen, The Netherlands).
Preparation of radiolabeled drugs
Cetuximab 5 mg/ml (Erbitux; Merck, Darmstadt, Germany),
etanercept (Enbrel; Immunex/Amgen, Thousand Oaks,
CA, USA) and anakinra 149 mg/ml (Kineret; Swedish
Orphan Biovitrum AB, Stockholm, Sweden) were dia-
lyzed against 50 mM phosphate buffer, pH 7.4, and
radiolabeled with iodine-125 (PerkinElmer, Waltham,
MA, USA). For radioiodination, the Iodogen method
was applied. Briefly, 100 μg of cetuximab, 300 μg of
etanercept, and 300 μg of anakinra were incubated in a
tube coated with 100 μg 1,3,4,6-tetrachloro-3α,6α-
diphenylglycouril (Iodogen) (Thermo Fisher Scientific,
Waltham, MA, USA) with 50–72 MBq I-125 in phos-
phate buffer, pH 7.4, for 10–60 mins. Labeling effi-
ciency was 68–90 %, and the radioiodinated products
were purified by gel filtration on a PD-10 column (GE
Healthcare Bio-Sciences, Uppsala, Sweden) that was
eluted with phosphate-buffered saline and 0.5 % bovine
serum albumin. The radiochemical purity was deter-
mined by instant thin-layer chromatography and
exceeded 95 % for all preparations.
Animals and procedures
All animal procedures were conducted in accordance
with Radboud University Medical Center animal welfare
guidelines. Nine male Sprague–Dawley rats with an
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average weight of 250 g were anesthetized with 2.5–3 %
isoflurane inhalation anesthesia and injected with 150 μl of
I-125–labeled cetuximab (146 kDa), etanercept (51 kDa),
and anakinra (17 kDa). Drugs with different molecular
weights were selected to determine the effect of molecular
weight on central delivery. For each drug, two rats were
given injections in the area overlying the cervical spine at
the C6-C7 level using a 30-gauge needle at a depth of 6
mm as described by Tobinick et al. [16]. One rat was given
an injection in the dorsal tail vein, followed by flushing
with 1 ml of saline. Directly after injection, the rats were
placed in head-down position for 3 minutes. Five minutes
after the injection, single-photon emission computed tom-
ography (SPECT) was performed using a U-SPECT-II/CT
scanner (MILabs, Utrecht, the Netherlands). After com-
pletion of scanning, which took 20 minutes, all rats were
euthanized and bio-distribution was determined.
Results
SPECT imaging did not reveal intracranial accumulation
of the radioiodinated drugs in all but one of the animals
(Fig. 1a). This animal, the first rat that received an injec-
tion, died during acquisition of the SPECT scan, and
distribution of the tracer was compatible with the ana-
tomic margins of the ventricular system and the intrasp-
inal cerebrospinal fluid space. In the other animals,
radiolabeled drugs could be detected only in the injection
region (Fig. 1b), without any sign of penetration into the
CNS.
The biodistribution of the radiolabeled drugs is sum-
marized in Table 1, in which the uptake in the heart,
blood, brain, and perispinal injection region is specified.
Except for the first rat, deposition of drugs in the brain
was ≤0.10 % injected dose per gram of tissue (%ID/g).
After injection into the dorsal tail vein, the average dis-
tribution was higher in blood and in the heart. After
perispinal injection, the drugs accumulated locally and
did not reach the brain.
Discussion
In this study, the previous claim that radiolabeled
drugs accumulate in the brain after perispinal injec-
tion [11, 16, 18] could not be replicated. In only one
of the rats, deposition of I-125-labeled cetuximab in
the brain regions compatible with the intraventricular
Fig. 1 In vivo distribution of iodine-125 (I-125)–labeled cetuximab after perispinal injection using single-photon emission computed tomography
(SPECT). a Biodistribution of I-125–labeled cetuximab suggested the injection to be intrathecal instead of perispinal. b The biodistribution displayed is
in line with images of the other four animals that received perispinal injections. The radiolabeled drug in these animals was found only at the injection
site
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system could be detected. In the other animals, drugs
accumulated locally at the injection site.
The first rat that received an injection died in the
SPECT scanner (<20 minutes after administration). In
the same rat, accumulation of the tracer in the peri-
spinal region was very low compared with that in the
other rats (0.06 %ID/g), which supports the suspicion
of a “false route” during injection. When, according to
the protocol, the drug is blindly injected in the peri-
spinal region at a depth of 6 mm, there is a high change
of injecting intrathecally. In this study, drugs had to be
administered carefully to prevent this misrouting. In
the experiment by Tobinick et al., injection might have
been directly into the intrathecal space and not into the
perispinal soft tissues. As such, the recommendations
by Tobinick et al. to use the VVS as a drug delivery
route into the CNS lacks any scientific basis.
Conclusions
We believe that there is lack of proof that perispinal in-
jection of drugs like etanercept would lead to effective
concentrations in the brain. Before this technique can
be recommended for treatment in patients with AD
and other neurologic diseases, proof of concept is
needed. However, our present experiments falsified the
claim by Tobinick et al. about the vertebral venous
system being an anatomical route to bypass the blood-
brain-barrier and to deliver high molecular drugs to the
central nervous system. Based on the literature, and the
now available new data, we feel that there is even insuf-
ficient basis to propose an RCT at this point.
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